Back to News
Market Impact: 0.3
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Source: benzinga.com
Healthcare & BiotechAntitrust & Competition
Dyne Therapeutics shares traded lower Tuesday following Novartis' release of global Phase 3 HARBOR study data for del-desiran in myotonic dystrophy type 1. The reaction highlights increased competitive pressure in the DM1 treatment market, though the article provides no clinical efficacy, safety, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
DYN-0.45
NVS0.50
More News
- Newamsterdam Pharma stock hits 52-week low at 19.57 USD
- Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Scalpers offer Apple iPhone Duo buyers hundreds extra outside Beijing launch